Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-ADSCs for 2nd and 3rd Degree Burn Wounds
NCT03113747Phase 2Unknown
- Sponsor
- AA-Partners
- Start
- Mar 2015
- Primary completion
- Dec 2018
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of allo-asc in burn injury (2 arms), sponsored by AA-Partners. Primary endpoints: Degree of healing of skin flap at 1 month and Degree of epithelialization of burn wounds in the perforations of a skin graft at 1 month. Status: unknown.
02
Drugs
allo-asc
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT03113747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113747.